Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
European Society for Medical Oncology (ESMO)
ESMO 2014 – Immuno-Oncology
ESMO 2014 – Immuno-Oncology
Dose-Ranging Phase 2 Results of Nivolumab Therapy in Metastatic Renal-Cell Carcinoma
ESMO 2014 – Immuno-Oncology
Read More ›
Pembrolizumab in the Treatment of Patients with Advanced Urothelial Tract Cancer
ESMO 2014 – Immuno-Oncology
Read More ›
Long-Term Follow-Up Results of MPDL3280A in Metastatic Renal-Cell Carcinoma
ESMO 2014 – Immuno-Oncology
Read More ›
Anti–PD-L1 Monoclonal Antibody MPDL3280A in Metastatic Urothelial Bladder Cancer
ESMO 2014 – Immuno-Oncology
Read More ›
Updated OS Data for the CA184-043 Trial: Immunotherapy with Ipilimumab Does Not Improve Survival in Patients with Metastatic Prostate Cancer
ESMO 2014 – Immuno-Oncology
Read More ›
Two Dosing Schedules of Pembrolizumab for Patients with Advanced Melanoma
ESMO 2014 – Immuno-Oncology
Read More ›
Nivolumab Improves Survival in Ipilimumab-Naïve Patients with Advanced Melanoma
ESMO 2014 – Immuno-Oncology
Read More ›
Nivolumab versus Investigator’s Choice of Chemotherapy in Patients with Advanced Melanoma
ESMO 2014 – Immuno-Oncology
Read More ›
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us